Literature DB >> 19559585

Human innate immunity against African trypanosomes.

Etienne Pays1, Benoit Vanhollebeke.   

Abstract

Humans are naturally resistant to infection by the African trypanosome prototype Trypanosoma brucei brucei, and only two variant clones of this parasite can avoid this innate immunity and cause sleeping sickness. The resistance to T. brucei is due to serum complexes associating apolipoprotein A-1 (apoA1) with two primate-specific proteins, apolipoprotein L-1 (apoL1) and haptoglobin-related protein (Hpr). We discuss recent advances on the respective functions of apoL1 and Hpr in this system. ApoL1 was found to share structural and functional similarities with proteins of the apoptotic Bcl2 family, and to kill trypanosomes through anionic pore formation in the lysosomal membrane of the parasite. In association with hemoglobin (Hb), Hpr was found to promote the binding of the trypanolytic complexes to a haptoglobin (Hp)-Hb receptor of the trypanosome surface, hereby facilitating the internalization of apoL1. Hpr or apoL1 deficiency respectively leads to the reduction or abolishment of human protection against T. brucei.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19559585     DOI: 10.1016/j.coi.2009.05.024

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  31 in total

Review 1.  Crosstalk between reverse cholesterol transport and innate immunity.

Authors:  Kathleen M Azzam; Michael B Fessler
Journal:  Trends Endocrinol Metab       Date:  2012-03-10       Impact factor: 12.015

2.  The role of HDL in innate immunity.

Authors:  Kenneth R Feingold; Carl Grunfeld
Journal:  J Lipid Res       Date:  2010-10-13       Impact factor: 5.922

Review 3.  Target organ damage in African American hypertension: role of APOL1.

Authors:  Barry I Freedman; Mariana Murea
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

4.  APOL1 risk variants, race, and progression of chronic kidney disease.

Authors:  Afshin Parsa; W H Linda Kao; Dawei Xie; Brad C Astor; Man Li; Chi-yuan Hsu; Harold I Feldman; Rulan S Parekh; John W Kusek; Tom H Greene; Jeffrey C Fink; Amanda H Anderson; Michael J Choi; Jackson T Wright; James P Lash; Barry I Freedman; Akinlolu Ojo; Cheryl A Winkler; Dominic S Raj; Jeffrey B Kopp; Jiang He; Nancy G Jensvold; Kaixiang Tao; Michael S Lipkowitz; Lawrence J Appel
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

Review 5.  Genetics of kidney failure and the evolving story of APOL1.

Authors:  David J Friedman; Martin R Pollak
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

Review 6.  The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus.

Authors:  Saharon Rosset; Shay Tzur; Doron M Behar; Walter G Wasser; Karl Skorecki
Journal:  Nat Rev Nephrol       Date:  2011-05-03       Impact factor: 28.314

Review 7.  Trypanosomal immune evasion, chronicity and transmission: an elegant balancing act.

Authors:  Paula MacGregor; Balazs Szöőr; Nicholas J Savill; Keith R Matthews
Journal:  Nat Rev Microbiol       Date:  2012-04-30       Impact factor: 60.633

8.  Diagnostic value of blood gene expression signatures in active tuberculosis in Thais: a pilot study.

Authors:  N Satproedprai; N Wichukchinda; S Suphankong; W Inunchot; T Kuntima; S Kumpeerasart; S Wattanapokayakit; S Nedsuwan; H Yanai; K Higuchi; N Harada; S Mahasirimongkol
Journal:  Genes Immun       Date:  2015-03-12       Impact factor: 2.676

9.  The major yolk protein vitellogenin interferes with the anti-plasmodium response in the malaria mosquito Anopheles gambiae.

Authors:  Martin K Rono; Miranda M A Whitten; Mustapha Oulad-Abdelghani; Elena A Levashina; Eric Marois
Journal:  PLoS Biol       Date:  2010-07-20       Impact factor: 8.029

10.  Plasma apolipoprotein L1 levels do not correlate with CKD.

Authors:  Leslie A Bruggeman; John F O'Toole; Michael D Ross; Sethu M Madhavan; Marlene Smurzynski; Kunling Wu; Ronald J Bosch; Samir Gupta; Martin R Pollak; John R Sedor; Robert C Kalayjian
Journal:  J Am Soc Nephrol       Date:  2013-11-14       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.